Our Mission
is to collaborate with community stakeholders to establish standards suited for the manufacturing, distribution, dispensing, and consumption of Cannabis-based medicine.
Classified as Schedule III, Cannabis is subject to provisions of the Food and Drug Cosmetic Act (FDCA). For example, a drug containing Cannabis would need FDA approval to be lawfully introduced into interstate commerce. Only two botanical drug applications have been approved by the FDA.
Consumers reject the idea of federally approved Cannabis. Why would they trust a historically restrictive process that has produced questionable quality? Despite decades of prohibitive laws and top-down suppression, Cannabis continues to be a viable grass-roots commodity valuable for health and well-being.
The Consortium proposes an alternative framework…
For people who access Cannabis from a neighbor or grow their own.
…. the Consortium studies real-world Cannabis consumption.
For all Cannabis Operators
…. the Consortium develops product standards.
For people who use State approved dispensaries
…. the Consortium refers to safe and effective Cannabis products.
Scientist Spotlight
Jeff Tarrant, Ph.D., BCN is the founder and Director of the Neuromeditation Institute. He is a licensed psychologist and board certified in neurofeedback. Dr. Tarrant is also the Chief Science Officer for Healium XR, creating biometrically controlled virtual and augmented reality experiences. In addition, Dr. Tarrant is a Scientific Advisor to both Divergence Neuro and Neuphony, creators of cloud-based neurofeedback software and wireless EEG headsets.Dr. Tarrant specializes in teaching, clinical applications, and research combining technology- based interventions with meditative states for improved mental health. His research focuses on exploring brainwave changes that occur as a result of contemplative practices, technological interventions, and non-ordinary states of consciousness. Dr. Tarrant is the author of the books, Meditation Interventions to Rewire the Brain, 3 book chapters, and 15 research articles focused on virtual and augmented reality, meditation, and neurofeedback.
In 2019, Dr. Tarrant conducted a pilot study titled, “A comparison of three cannabis strains using EEG and psychological measures: Implications for therapeutic applications.” This study was presented at the 2019 Emerald Conference and revealed different EEG and subjective effects across 3 chemotypes. These results suggest that there may be specific therapeutic applications for different chemotypes based on the EEG response of the user. Additional research is needed to establish if it is possible to predict therapeutic benefits of specific cannabis strains based on the EEG effects.
Initiatives
The Dosing Project
Observational studies have an immediate impact in predicting the safety and efficacy of community accessible Cannabis products. This initiative crowd sources data from current Cannabis users which translates into a foundational analysis of botanical dose-effect relationships.
The Cannabis Mind
Current debate on the psychoactive and non-psychoactive properties of Cannabis sativa L. requires addressing the acute mood-altering and cognitive effects after Cannabis use. Using objective and subjective scales, this initiative pursues a broader and more detailed understanding of the Cannabis Mind.
Clinical Correlates
Cannabinoids and Endocannabinoids mitigate immune and inflammatory influences. This initiative develops bioassays to define immunological role of Cannabis and the Endocannabinoid system (ECS) .
Agronomy Initiative
Developing data driven cultivation methodology and crop standardization using Onset HOBO data loggers to monitor and assess all aspects of cultivation and processing. Exploration of regional quality markers in product chemistry to validate or reject historically notorious cultivation regions.
Research Articles and Presentations
Discover our latest research findings on cannabis products
